These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31202833)

  • 21. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
    Tang L; Wu Y; Tian M; Sjöström CD; Johansson U; Peng XR; Smith DM; Huang Y
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E563-E576. PubMed ID: 28811292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapagliflozin Does Not Directly Affect Human α or β Cells.
    Dai C; Walker JT; Shostak A; Bouchi Y; Poffenberger G; Hart NJ; Jacobson DA; Calcutt MW; Bottino R; Greiner DL; Shultz LD; McGuinness OP; Dean ED; Powers AC
    Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32428240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
    Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
    PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
    Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut Microbiota-Tryptophan Metabolism-GLP-1 Axis Participates in β-Cell Regeneration Induced by Dapagliflozin.
    Jiang Y; Yang J; Xia L; Wei T; Cui X; Wang D; Jin Z; Lin X; Li F; Yang K; Lang S; Liu Y; Hang J; Zhang Z; Hong T; Wei R
    Diabetes; 2024 Jun; 73(6):926-940. PubMed ID: 38471012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
    Yabiku K; Nakamoto K; Tsubakimoto M
    J Diabetes Res; 2020; 2020():1682904. PubMed ID: 33457424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
    Fushimi Y; Obata A; Sanada J; Nogami Y; Ikeda T; Yamasaki Y; Obata Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    Sci Rep; 2021 Aug; 11(1):16120. PubMed ID: 34373487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1/AMPK/PGC1α/FoxO1 axis.
    Hassan HA; Nageeb MM; Mohammed HO; Samy W; Fawzy A; Afifi R; Abbas NAT
    Toxicol Appl Pharmacol; 2024 Aug; 489():116991. PubMed ID: 38871090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
    Solis-Herrera C; Daniele G; Alatrach M; Agyin C; Triplitt C; Adams J; Patel R; Gastaldelli A; Honka H; Chen X; Abdul-Ghani M; Cersosimo E; Del Prato S; DeFronzo R
    Diabetes Care; 2020 May; 43(5):1065-1069. PubMed ID: 32144165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
    Ferrannini E; Baldi S; Frías JP; Guja C; Hardy E; Repetto E; Jabbour SA; DeFronzo RA
    Diabetes Obes Metab; 2020 Jan; 22(1):99-106. PubMed ID: 31469220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
    Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
    J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
    Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
    Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Report: DKA with Lower-than-Expected Blood Glucose in the Setting of SGLT2 Inhibitor Use.
    Voskertchian A; Milanes L
    Am Fam Physician; 2021 Feb; 103(4):200. PubMed ID: 33587584
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.